Matthew D. Dallas
Keine laufenden Positionen mehr
Profil
Matthew D.
Dallas served as an Independent Director at Harvard Apparatus Regenerative Technology, Inc. from 2018 to 2020.
Prior to that, he was the Chief Financial Officer & Treasurer at CoLucid Pharmaceuticals, Inc. from 2015 to 2017 and the Treasurer, Chief Accounting Officer & VP-Finance at AVEO Pharmaceuticals, Inc. from 2011 to 2015.
He also served as the Chief Financial Officer at AVEO Pharmaceuticals, Inc. from 2017 to 2019.
Currently, he is the Chief Financial Officer & Senior Vice President at Zealand Pharma A, a position he has held since 2019.
Mr. Dallas received his undergraduate degree from the University of Tennessee.
Ehemalige bekannte Positionen von Matthew D. Dallas
| Unternehmen | Position | Ende |
|---|---|---|
| ZEALAND PHARMA A/S | Director of Finance/CFO | 31.08.2022 |
| HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC. | Director/Board Member | 03.02.2020 |
| AVEO PHARMACEUTICALS, INC. | Director of Finance/CFO | 26.09.2019 |
| COLUCID PHARMACEUTICALS INC | Director of Finance/CFO | 01.03.2017 |
| AVEO PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 06.02.2015 |
Ausbildung von Matthew D. Dallas
| University of Tennessee | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC. | Health Technology |
| ZEALAND PHARMA A/S | Health Technology |
| Private Unternehmen | 2 |
|---|---|
CoLucid Pharmaceuticals, Inc.
 CoLucid Pharmaceuticals, Inc. BiotechnologyHealth Technology CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA. | Health Technology |
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
